Related Experiment Video
Updated: Jul 26, 2026
10:39
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
Interleukin-5: a drug target for allergic diseases
1Western Australian Institute for Medical Research & Curtin University of Technology, Level 5 MRF Building, Rear 50 Murray Street, Perth 6000, Australia. colin@cyllene.uwa.edu.au
Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
Summary
Interleukin-5 (IL-5) drives eosinophil activity in asthma, making it a key target for new anti-asthmatic drugs. This review explores drug discovery strategies and compounds targeting IL-5 pathways.
Area of Science:
- Immunology
- Pharmacology
- Respiratory Medicine
Background:
- Eosinophils play a critical role in the allergic inflammatory response characteristic of asthma.
- Interleukin-5 (IL-5) is a central cytokine regulating eosinophil production, activation, localization, and survival.
Purpose of the Study:
- To review IL-5 as a therapeutic target for novel anti-asthmatic drug development.
- To discuss various drug discovery strategies and screening assays for IL-5 inhibitors.
Main Methods:
- Review of existing literature on IL-5 biology and anti-asthmatic drug discovery.
- Analysis of different approaches including inhibition of IL-5 production, receptor antagonism, and modulation of receptor expression/activation.
Main Results:
- IL-5's unique role in eosinophil regulation positions it as a crucial target for asthma treatment.
- Multiple drug discovery avenues are being pursued, focusing on inhibiting IL-5 signaling pathways.
Conclusions:
- Targeting IL-5 offers a promising strategy for developing effective anti-asthmatic therapies.
- Ongoing research focuses on identifying and developing specific compounds and screening assays for IL-5 targeted drug discovery.
Related Concept Videos
01:27Allergic Drug Reactions
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...